CNTA
CNTA clinical trials: Centessa Pharmaceuticals plc
Every trial on ClinicalTrials.gov where Centessa Pharmaceuticals plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 6
- As lead sponsor
- 10
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CNTA on the catalyst calendar · CNTA registry changes
- Primary completion Sep 30, 2027Sponsor estimatePhase 2/Phase 3NCT07598708A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of...Centessa Pharmaceuticals (UK) Limited · Narcolepsy Type 1RecruitingCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06752668A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited · Narcolepsy Type 1RecruitingCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026Sponsor estimatePhase 2NCT07096674A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaCentessa Pharmaceuticals (UK) Limited · Narcolepsy Type 1RecruitingCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 1NCT07413666A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 YearsCentessa Pharmaceuticals (UK) Limited · Healthy Adult Male and Female VolunteersRecruitingCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2026Sponsor estimatePhase 1NCT07082829A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of AgeCentessa Pharmaceuticals (UK) Limited · Excessive Daytime SleepinessRecruitingCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2025ActualPhase 1/Phase 2NCT05821777A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid TumorsCentessa Pharmaceuticals (UK) Limited · Advanced Solid TumorTerminatedCNTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2024ActualPhase 2NCT05789537A Study of SerpinPC in Participants with Hemophilia B (HemB) with InhibitorsApcinteX Ltd · Hemophilia B with InhibitorTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2024ActualPhase 2NCT05789524The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia BApcinteX Ltd · Hemophilia aTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2025ActualPhase 3NCT06568302The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical TrialApcinteX Ltd · Hemophilia aTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2024ActualNo phase registeredNCT05605678Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)ApcinteX Ltd · Hemophilia aTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2024ActualPhase 1/Phase 2NCT04073498The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)ApcinteX Ltd · Hemophilia aCompletedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2023ActualPhase 1NCT05323110Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy VolunteersCapella Bioscience Ltd · Chronic Inflammatory DiseaseTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2022ActualPhase 3NCT05208866Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303Palladio Biosciences · Polycystic Kidney Disease, AdultTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2022ActualPhase 3NCT04152837Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney DiseasePalladio Biosciences · Polycystic Kidney Disease, AdultTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2022ActualPhase 3NCT04064346Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney DiseasePalladio Biosciences · Autosomal Dominant Polycystic KidneyTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 12, 2022ActualPhase 1NCT04443192A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ SubjectsZ Factor Limited · Alpha1 Anti-Trypsin DeficiencyTerminatedCNTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner